Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Waldencast plc - Class A Ordinary Share (NQ:WALD)

1.650 -0.180 (-9.84%)
Streaming Delayed Price Updated: 10:18 AM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 34,125
Open 1.830
Bid (Size) 1.640 (100)
Ask (Size) 1.670 (200)
Prev. Close 1.830
Today's Range 1.615 - 1.850
52wk Range 1.450 - 3.630
Shares Outstanding 9,342,874
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Moxie selected as a leading aesthetic practice software and support partner for its commitment to innovation, compliance, and empowering aesthetic entrepreneurs 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
The dermatologist-tested duo pairs gentle chemical resurfacing with daily hydration and SPF protection for visibly smoother lips 
From Waldencast plc
Via GlobeNewswire

Performance

YTD
-3.5%
-3.5%
1 Month
+1.9%
+1.9%
3 Month
-9.8%
-9.8%
6 Month
-1.8%
-1.8%
1 Year
-53.3%
-53.3%

More News

Read More
News headline image
Obagi Medical and VIO Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Next Health Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
UPDATE - Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
CORRECTION – Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Unveils ALOHA Program to Launch Obagi® saypha® MagIQ™ – Pioneering the Largest Real-World Evaluation of a New Hyaluronic Acid Filler
From Waldencast plc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
From Waldencast plc
Via GlobeNewswire
News headline image
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation
From Waldencast plc
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
Earnings Scheduled For August 18, 2025 ↗
Via Benzinga
News headline image
Waldencast Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗
Via Benzinga
News headline image
Gore Range Capital Announces Sale of Novaestiq Corp. to Waldencast
Via ACCESS Newswire
News headline image
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
From Waldencast plc
Via GlobeNewswire
News headline image
Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Waldencast plc - Class A Ordinary Share publicly traded?
Yes, Waldencast plc - Class A Ordinary Share is publicly traded.
What exchange does Waldencast plc - Class A Ordinary Share trade on?
Waldencast plc - Class A Ordinary Share trades on the Nasdaq Stock Market
What is the ticker symbol for Waldencast plc - Class A Ordinary Share?
The ticker symbol for Waldencast plc - Class A Ordinary Share is WALD on the Nasdaq Stock Market
What is the current price of Waldencast plc - Class A Ordinary Share?
The current price of Waldencast plc - Class A Ordinary Share is 1.650
When was Waldencast plc - Class A Ordinary Share last traded?
The last trade of Waldencast plc - Class A Ordinary Share was at 02/05/26 10:18 AM ET
What is the market capitalization of Waldencast plc - Class A Ordinary Share?
The market capitalization of Waldencast plc - Class A Ordinary Share is 15.42M
How many shares of Waldencast plc - Class A Ordinary Share are outstanding?
Waldencast plc - Class A Ordinary Share has 15M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.